Karo Bio, Wyeth extend atherosclerosis collaboration until 2009

TriMed Staff | | Health Imaging | Screening
Wyeth and Karo Bio have extended their atherosclerosis collaboration until Aug. 31, 2009, to identify and select development candidates for treatment of atherosclerosis and to evaluate additional clinical possibilities by targeting a nuclear hormone receptor, LXR.

The Stockholm, Sweden-based Karo said its collaboration with the Madison, N.J.-based Wyeth started in 2001 with the aim to develop new compounds for treatment of atherosclerosis with LXR as target receptor.

LXR is a regulator of cholesterol metabolism in mammals, and is targeted for prevention and treatment of atherosclerosis and dyslipidemia, according to the companies.    

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.